Rosiptor - Aquinox Pharmaceuticals

Drug Profile

Rosiptor - Aquinox Pharmaceuticals

Alternative Names: AQX 1125; Rosiptor acetate

Latest Information Update: 03 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aquinox Pharmaceuticals
  • Class Androstanes; Anti-inflammatories; Immunotherapies; Indenes; Small molecules
  • Mechanism of Action Inositol-1,4,5-trisphosphate 5-phosphatase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Haematological disorders; Hypersensitivity; Immunological disorders; Inflammation; Interstitial cystitis; Irritable bowel syndrome; Prostatitis; Pulmonary fibrosis

Most Recent Events

  • 08 Aug 2018 Discontinued - Phase-II for Allergic asthma in United Kingdom, Canada (PO)
  • 08 Aug 2018 Discontinued - Phase-II for Prostatitis in Canada, USA (PO)
  • 08 Aug 2018 Discontinued - Phase-III for Interstitial cystitis in Latvia, Netherlands, Spain, Romania, Belgium, United Kingdom, Poland, Canada, Czech Republic, Hungary, Denmark, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top